Primaquine is a potent antimalaria agent and a potent gametocytocide in falciparum malaria. Primaquine prevents relapse in vivax and ovale malaria.

MMV687807 is an anthelmintic agent which has a good activity against Toxoplasma gondii (T. gondii) with an IC50 value of 0.15 μM and a CC50 value of 1.69 μM.

RYL-552S kills drug-resistant strains of Plasmodium falciparum. RYL-552S can efficiently kill asexual blood-stage parasites in vitro.

Nullscript is a negative control for Scriptaid. Nullscript is a known inactive analog of Scriptaid. Scriptaid is a representative HDAC inhibitor. Nullscript inhibits Cryptosporidium (C. parvum) growth with the IC50 value of 2.1 μM.

SBI-0797750 (SBI 0797750) is a potent, fully selective PfGluPho inhibitor with robust nanomolar activity against recombinant PfGluPho, PvG6PD, and P. falciparum blood-stage parasites.SBI-0797750 disturbs the cytosolic glutathione-dependent redox potential, as well as the cytosolic and mitochondrial H2O2 homeostasis of P. falciparum blood stages, at low nanomolar concentrations.SBI-0797750 does not harm red blood cell (RBC) integrity and phagocytosis and thus does not promote anemia.

PDE-I2 is a potent and selective inhibitor of malaria proliferation with Pf IC50 of 18 nM.PDE-I2 is a precursor of the anticancer duocarmycin family that preserves the class's sequence-specific DNA binding but lacks its signature DNA alkylating cyclopropyl warhead.PDE-I2 retains comparable antimalarial potency to chloroquine.PDE-I2 is >1,000-fold less toxic to human cell lines than duocarmycin, with mitigated impacts on eukaryotic chromosome stability.PDE-I2 treatment induces severe defects in parasite nuclear segregation leading to impaired daughter cell formation during schizogony.

NEU-4438 (NEU4438) is a potent inhibitor of P. falciparum with EC50 of 13 nM (T. brucei), demonstrates improved aqueous solubility (880 uM) compared to NEU-1953; reduced parasitemia 109 fold in trypanosome-infected mice.

N205 is a novel anti-malaria compound with in vitro IC50 of 1.3 nM against Plasmodium falciparum (3D7); demonstrates excellent rodent pharmacokinetic and in vivo antimalarial efficacy studies in the mouse Plasmodium berghei and Plasmodium falciparum Pf3D70087/N9 severe combined immunodeficiency (SCID) mouse models.

MMV688533 is a potent antimalarial compound that displays fast parasite clearance in vitro and is not cross-resistant with known antimalarials, MMV688533 is highly potent against multiple P. falciparum strains with IC50 values in low nanomolar range (P. falciparum 3D7, IC50=1.9 nM).MMV688533 also showed excellent ex vivo activity against asexual blood-stage parasites from fresh P. falciparum isolates (median IC50=1.3 nM, range=0.02 to 6.3 nM).MMV688533 remained potent in ex vivo assays against both P. falciparum and P. vivax with IC50 of 18.9 and 12.0 nM respectively.MMV688533 displayed fast and potent in vivo efficacy and favorable in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetic properties.MMV688533 antiplasmodial activity is unrelated to existing antimalarials and selects for low-grade resistance mediated in part by mutations in PfACG1 and PfEHD.

MMV675968 is a potent, small molecule inhibitor of Toxoplasma gondii (T. gondii) with IC50 of 0.02 uM, via the pathogen box.MMV675968 has been shown to be efficient against the planktonic form of C. albicans.MMV675968 showed an antiplasmodial activity against P. falciparum.MMV675968inhibited the growth of all four A. baumannii test strains with IC50 of 0.6-2.7 uM, IC90 of 0.7-3.9 uM, and MIC of 1.6-10 uM.

MMV084978 (MMV 084978) is an antiplasmodial drug-like compound tageting Plasmodium falciparum acetyl-coenzyme A synthetase (PfAcAS), directly and selectively inhibit PfAcAS activity in vitro with IC50 of 370 nM.MMV084978 directly inhibits PfAcAS by preventing CoA and acetate binding.MMV084978 demonstrated in vitro efficacy (P. falciparum Dd2 EC50=150 nM) with increased liver-stage potency (Pbluc EC50= 520 nM).MMV084978 directly and selectively inhibit PfAcAS activity in vitro.

MMV019721 (MMV019721) is an antiplasmodial drug-like compound tageting Plasmodium falciparum acetyl-coenzyme A synthetase (PfAcAS), directly and selectively inhibit PfAcAS activity in vitro with IC50 of 73 nM.MMV019721 directly inhibits PfAcAS by preventing CoA binding.MMV019721 has activity against blood-stage parasites in vitro (P. falciparum 3D7, EC50=460 nM) and against liver-stage P. berghei parasites (Pbluc EC50=2,000 nM).MMV019721 directly and selectively inhibits PfAcAS activity in vitro.

CTN1122 (CTN-1122) is a potent, selective Leishmaniacasein kinase 1 isoform 2 (CK1.2, L-CK1.2) with IC50 of 0.72 uM (LmCK1) and 0.8 uM (amastigotes L. major), antileishmanial compound.

CTCB-405 (CTCB405) is a small molecule allosteric inhibitor of T. brucei phosphofructokinase (TbPFK) with IC50 of 0.18 uM, ITC Kd of 92 nM, no significant inhibition of human PFKs.CTCB-405 demonstrated in vitro parasite killing potency of the bloodstream form of T. brucei strain Lister 427 (EC50=0.37 uM).CTCB-405 (50, 100 mg/kg) clear parasites in a stage 1 model of HAT infection with 1-day oral dosing and show reduction of parasitaemia in the brain in a pleiomorphic model.

Antimalarial agent 10 (Compound 17b) is an aminoalcohol quinoline compound. Antimalarial agent 10 is an antimalarial agent with IC50 values of 14.9 nM and 11.0 nM against respectively Pf3D7 and PfW2 and a selectivity index higher than 770 whatever the cell line is.

HDAC1-IN-4 (JX34) is a potent Plasmodium falciparum HDAC1 inhibitor shows antimalarial activity (IC50 < 5 nM) and lower cytotoxicity.

CRK12-IN-1 is a potent CRK12 inhibitor. CRK12-IN-1 is extremely potent against T.b. brucei and rapidly cytocidal, as well as equally potent against T. congolense and T. vivax (EC50 of 1.3 and 18 nM, respectively).

Epoxyazadiradione is a limonoid purified from neem (Azadirachta indica) fruits. Epoxyazadiradione inhibits the tautomerase activity of MIF of both human (huMIF) and malaria parasites (Plasmodium falciparum (PfMIF) and Plasmodium yoelii (PyMIF)) non-competitively in a reversible fashion (Ki, 2.11-5.23 μM). Epoxyazadiradione has the potential against proinflammatory reactions induced by MIF of both malaria parasites and human.

Cycloaspeptide A, isolated from the endophytic fungus Penicillium janczewskii, has antiparasitic activity.

19,20-Epoxycytochalasin D, a cytochalasin, is a fungal metabolite from Nemania sp. 19,20-Epoxycytochalasin D shows potent in vitro antiplasmodial activity and phytotoxicity.

19,20-Epoxycytochalasin C, a cytochalasin, is a fungal metabolite from Nemania sp. 19,20-Epoxycytochalasin C shows potent in vitro antiplasmodial activity and phytotoxicity.

Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC50 value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines.

Derquantel is a potent anthelmintic. Derquantel causes flaccid paralysis and expulsion of nematodes.

Asterriquinol D dimethyl ether is a fungal metabolite, which can inhibit mouse myeloma NS-1 cell lines with an IC50 of 28 μg/mL. Asterriquinol D dimethyl ether also inhibits Tritrichomonas foetus.

P-orlandin, a fungal metabolite, prevents FREP1 from binding to gametocytes or ookinetes. P-orlandin effectively inhibits P. falciparum infection in mosquitoes.

Teclozan (WIN 13146) is an antiprotozoal agent, class in benzylamine derivatives. Teclozan intervenes in the phospholipid metabolism preventes the formation of arachidonic acid. Teclozan acts in the intestinal lumen being effective in Anti-G. intestinalis. Teclozan can be used for the research of protozoan infections.

Miaosporone A, an angucyclic quinone, exhibits antimalarial activity against Plasmodium falciparum K1 and antibacterial activity against Mycobacterium tuberculosis with respective IC50 values of 2.5 and 2.4 μM and displays cytotoxic activities against both cancerous (MCF-7 and NCI-H187) and nonmalignant (Vero) cells.

Asperaculane B is a fungal metabolite against P. falciparum transmission with an IC50 of 7.89 µM. Asperaculane B also inhibits the development of asexual P. falciparum with IC50 of 3 µM, and it is nontoxic to human cells.

Pulixin prevents FREP1 from binding to P. falciparum-infected cell lysate. Pulixin blocks the transmission of the parasite to mosquitoes with an EC50 of 11 µM. Pulixin also inhibits the proliferation of asexual-stage P. falciparum with an EC50 of 47 nM.

Diethylcarbamazine is a microfilaricidal drug used originally in onchocerciasis and lymphatic filiariasis study.